Without a Ribbon
  • About
    • Events
    • Get In Touch
  • Rare Cancer Resources
  • Shop
  • How You Can Help
  • Meet Warriors
  • News
  • Login
  • Register

Select Page

HELP

LEARN

EVENTS

NUT Carcinoma (formerly called NUT Midline Carcinoma)

Become part of our growing rare cancer community.
Join our Facebook support group

Join Now

Posted by fatima.shakeel@opmc.co | Jan 28, 2025

What is NUT Midline Carcinoma?

NUT Midline Carcinoma is a rare and aggressive cancer caused by a genetic mutation. This mutation occurs when the NUT gene fuses with another gene, typically BRD4, leading to the production of abnormal proteins. These proteins drive uncontrolled cell growth, resulting in tumour development.

Causes

  • The condition arises from a genetic mutation where the NUT gene fuses with another gene, most commonly BRD4.
  • This mutation produces abnormal fusion proteins that lead to unregulated cell proliferation and tumour formation.

Signs and Symptoms

The symptoms vary depending on the tumour’s location and may include:

  • Nasal congestion or blockage
  • Loss of sense of smell
  • Sinus pressure or discomfort
  • Persistent cough
  • Shortness of breath
  • Chronic fatigue
  • General discomfort
  • Unintentional weight loss

Diagnosis

Diagnosing NUT Midline Carcinoma involves a series of tests:

1. Imaging Tests:

CT scans or MRIs help identify the tumour’s location, size, and blood supply.

2. Biopsy:

A tissue sample from the tumour is analysed under a microscope to confirm the diagnosis.

3. Immunohistochemistry:

Specialised tests are used to differentiate NUT carcinoma from other tumour types.

Treatment

  • Surgery: Complete surgical removal of the tumour and affected tissues is the primary treatment.
  • Radiation Therapy: Often used alongside surgery to reduce the risk of recurrence.
  • Chemotherapy: Recommended for advanced or metastatic cases.
  • New Targeted Therapies: Experimental drugs are being developed to inhibit NUT-fusion proteins, offering potential new treatment options.

Prognosis

  • NUT Midline Carcinoma is highly aggressive, with an average survival time of 9–10 months.
  • The 2-year survival rate is approximately 30%. Early diagnosis and advancements in targeted therapies are crucial for improving outcomes.

NUT Midline Carcinoma requires a comprehensive approach for diagnosis and treatment. Ongoing research into targeted therapies offers hope for better management and improved survival rates.


You can help us with your donation:

Without a Ribbon is a charity that works hard to aid those who suffer from rare cancers. You can help our cause in a variety of ways:

Donations — Without a Ribbon is grateful when we receive every donation. Giving to Without a Ribbon helps us to provide ongoing support, organise the annual gathering and subsidise the costs of our Warriors attending these conferences.
Sponsorship — If you wish to sponsor our charity, please contact us using this form.
Volunteering — We are always looking for volunteers to help with different aspects of running our charity. So, if you are looking for volunteer work, please feel free to contact us.

Share:

PreviousOur New Resource Page for Pancreatoblastoma
NextOur New Resource Page for NUT Carcinoma

If you need any help or advice just

Get In Touch

© Without a Ribbon 2019. All rights reserved.Powered by WEB 105 Creative

Stay up to date.

Sign up to our newsletter